AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01575080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour TS Blood Glucose Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
Study NCT02889224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obese
Study NCT02889224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercortisolism
Study NCT02889224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Study NCT02889224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study NCT03369574 — intervention group
Intervention type: DRUG
Intervention: Reslizumab
Description: reslizumab administration
Study NCT01339039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
Study NCT01339039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
Study NCT01339039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
Study NCT01339039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Daily administration for 5-9 days prior to surgery
Study NCT01339039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
Study NCT02112253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator ventral electrode up to 2 mA
Study NCT02112253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator ventral electrode up to 3 mA
Study NCT02112253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator dorsal electrode up to 2 mA
Study NCT02112253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator dorsal electrode up to 3 mA
Study NCT02112253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulator empirical programming
Study NCT01187316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
Study NCT01187316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
Study NCT00905996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection in gastric varix
Study NCT00905996 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta-blocker (propranolol)
Study NCT03839134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe® Comfort Injection System
Description: Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
Study NCT03839134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
Study NCT03839134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
Study NCT03597737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain APP
Description: pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study NCT02228252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein
Study NCT02228252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein
Study NCT02228252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten protein
Study NCT03602105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises in group and/or individually
Study NCT01443858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
Study NCT01443858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.
Study NCT01443858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.
Study NCT04192253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Study NCT01443858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
Study NCT03588130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx (5% EX-02 formulation)
Description: Active arm
Study NCT03588130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Description: Control arm
Study NCT03588130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical standard of care (NSSOC)
Description: Santyl (Enzymatic debridement) or commercially approved Hydrogel
Study NCT03195439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTP
Description: TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
Study NCT04817332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Selective, competitive, and reversible inhibitor of DPP1
Study NCT04817332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT03553576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low volume bolus
Description: Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
Study NCT03553576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High volume bolus
Description: Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
Study NCT03612583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung- and Diaphragm-Protective Ventilation
Description: Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
Study NCT03179358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-REX Ring-locking Procedure
Description: The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC
Study NCT03255694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Study NCT02216383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
Study NCT02216383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
Study NCT02216383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntometrine
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
Study NCT01061996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
Study NCT00666302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: topical
Study NCT00666302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus cream
Description: topical
Study NCT00830128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
Study NCT01090180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
Study NCT01090180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: inactive
Study NCT04266899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Drop Stimulator - Neuro Orthosis
Description: The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
Study NCT04266899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Gait training on a treadmill
Study NCT00846053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET
Description: All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
Study NCT04534998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy
Description: Partial nephrectomy for localized kidney cancer as curative treatment.
Study NCT04534998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial nephrectomy
Description: Partial nephrectomy for localized kidney cancer as curative treatment.
Study NCT01876108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
Study NCT03994913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-CD19 T Cells
Description: The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion.
Study NCT02831582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Given PO.
Study NCT02831582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO.
Study NCT01654770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: video capsule endoscopy
Study NCT01654770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon enteroscopy
Study NCT01826942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis UltraPulse single fractional CO2 laser treatment thin skin
Study NCT01826942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single fractional CO2 treatment at surgical area closure procedure on thick skin
Study NCT00260988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin (dalteparin)
Description: 200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
Study NCT00260988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innohep (tinzaparin)
Description: 175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
Study NCT01560247 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy using a MindFrame device
Study NCT03603522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia-DSM17938
Description: 2mL per day (1x10\^9 CFU) per day taken orally for 28 days
Study NCT03603522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BioGaia-DSM17938
Description: 2mL per day (1x10\^9 CFU) per day taken orally for 28 days
Study NCT03603522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Placebo Control
Description: 2mL per day of placebo formulation taken orally for 28 days
Study NCT03603522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Control
Description: 2mL per day of placebo formulation taken orally for 28 days
Study NCT01643330 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (MYDICAR)
Description: Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
Study NCT01643330 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intracoronary infusion
Study NCT02728323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
Study NCT02728323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20 ml of saline saline by intramuscular injection, at the end of surgery
Study NCT02524639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
Study NCT04415346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014 Inj
Description: Clostridium botulinum type A
Study NCT00781053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P144 cream
Description: P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
Study NCT00866905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: 40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
Study NCT00866905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
Study NCT03310216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Order I of visual inspection
Description: Participants in group I are provided AI visual inspection system first and EDTRS later.
Study NCT03310216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Order II of visual inspection
Description: The participants in Group II are provided EDTRS first and AI visual inspection system later.
Study NCT02837926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Study NCT02837926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil vaccine
Study NCT02837926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Study NCT02100046 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zarontin® (ethosuximide) and Stodal®
Study NCT02100046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zarontin® (ethosuximide) and Stodal®
Study NCT00913341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Study NCT00913341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Tablets, 1 mg (The Upjohn Company)
Study NCT01028781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
Study NCT03440476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-checkup to go
Description: The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
Study NCT03440476 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: e-checkup to go
Description: The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
Study NCT03440476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback-only booster
Description: Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.